This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
E2730
Catalog No. T79399 CAS
1520073-91-9
E2730 is a selective and noncompetitive inhibitor of the gamma-aminobutyric acid (GABA) transporter 1 (GAT1) that exhibits oral availability as well as antiepileptic properties. Its inhibition of GAT1 is dependent on the prevailing GABA concentrations and specifically targets GAT1-mediated GABA uptake. Demonstrating in vivo effectiveness, E2730 has been tested at doses ranging from 5-50 mg/kg orally in various models, including the rat amygdala kindling and the mouse corneal kindling models, as well as in drug-resistant psychomotor epilepsy, fragile X syndrome at 2.5-300 mg/kg, and Dravet syndrome at dosages of 10 mg/kg and 20 mg/kg [1].
All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
This compound is a customized synthesis product. We have a strong synthesis team with excellent synthesis technology and capabilities. However, due to various objective factors, there is a low probability that the synthesis will not be successful. If you need to learn more, please feel free to consult us, we will serve you wholeheartedly.
Contact us for more batch information
Biological Description
Chemical Properties
Storage
& Solubility Information
Description
E2730 is a selective and noncompetitive inhibitor of the gamma-aminobutyric acid (GABA) transporter 1 (GAT1) that exhibits oral availability as well as antiepileptic properties. Its inhibition of GAT1 is dependent on the prevailing GABA concentrations and specifically targets GAT1-mediated GABA uptake. Demonstrating in vivo effectiveness, E2730 has been tested at doses ranging from 5-50 mg/kg orally in various models, including the rat amygdala kindling and the mouse corneal kindling models, as well as in drug-resistant psychomotor epilepsy, fragile X syndrome at 2.5-300 mg/kg, and Dravet syndrome at dosages of 10 mg/kg and 20 mg/kg [1].
Molecular Weight
284.23
Formula
C9H8F4N2O2S
CAS No.
1520073-91-9
Storage
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Method for preparing DMSO master liquid: mg
drug pre-dissolved in μL DMSO (Master liquid concentration
mg/mL),
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL PEG300, mix and clarify, next add μL
Tween 80,mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation:Take μL
DMSO master liquid, next add μL Corn oil,mix and clarify.
Note:
Be sure to add the solvent(s) in order. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculator
Molarity Calculator
Dilution Calculator
Reconstitution Calculation
Molecular Weight Calculator
bottom
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.